Neuland Laboratories Limited has concluded fiscal year 2026 on a high note, reporting impressive financial results for the quarter ended March 31, 2026. The company achieved a total income of ₹788.7 crore for the quarter, marking a substantial 134.9% year-on-year growth. This performance reflects strong execution, customer satisfaction, and a solid foundation as the company continues to invest in strategic areas such as peptide manufacturing and research infrastructure.
Financial Performance Overview
Neuland Laboratories has demonstrated exceptional growth during Q4FY26 (January–March 2026). The company recorded a total income of ₹788.7 crore, representing a 76.1% increase over the previous quarter and a 134.9% surge compared to the same period last year. Profitability also saw significant expansion, with Profit After Tax (PAT) reaching ₹212.5 crore, a remarkable 666.3% increase year-on-year.
Operational Highlights
The company’s EBITDA for the quarter stood at ₹319.4 crore, with a robust EBITDA margin of 40.5%, reflecting a year-on-year improvement of 2,316 basis points. CEO and Managing Director Mr. Saharsh Davuluri attributed this performance to strong business visibility in the short to medium term, driven by both commercial and near-commercial molecules.
Strategic Investments and Future Outlook
Looking ahead, Neuland Laboratories is focused on sustainable growth through strategic capital allocation. Key initiatives include ongoing investments in Peptide Manufacturing and the construction of a new R&D Centre. These projects are progressing as planned and are central to the company’s long-term business development strategy, which aims to attract high-quality, sustainable projects to drive future innovation and operational success.
Earnings Call Information
To discuss these results in detail, the company will conduct an earnings call on Tuesday, May 12, 2026, at 17:30 hrs IST. Participants can register for the call via the company’s designated Diamond Pass Registration Link to engage with the management team.
Source: BSE
